The World Health Organization has approved the emergency use of the Sinovac vaccine developed by China.
In a written statement from the WHO, it was stated that the organization’s evaluation of the Sinovac vaccine, including inspections at the facilities where it was produced, was completed.
“The WHO today approved the Sinovac-CoronaVac Covid-19 vaccine for emergency use.” In the statement, it was pointed out that countries using this vaccine and other stakeholders have been assured that the Sinovac vaccine meets international standards for its efficacy and production.
In the statement, it was pointed out that Sinovac is an inactive vaccine and can be administered very easily due to its ease of storage.
The Strategic Advisory Group of Experts (SAGE), which advises WHO on the use of Covid-19 vaccines, has also completed its research on Sinovac, adding: “Based on the available evidence, the WHO recommends that this vaccine is administered in two doses. two to four weeks apart, in adults 18 years and over. recommend its use. expression was used.
WHO has not recommended an upper age limit for the vaccine.
“I AM HAPPY TO BE APPROVED”
Tedros Adhanom Ghebreyesus, director-general of the WHO, said he was happy that the emergency use of the new Sinovac vaccine developed by China had been approved.
At the press conference held at the organization’s headquarters in Geneva, Managing Director Ghebreyesus reiterated his call on world leaders to provide financial support for the new type of corona virus (Covid-19) Vaccines Global Access Program (COVAX) , which was established to support low- and middle-income countries.
Ghebreyesus stressed the importance of donating vaccines to COVAX to immunize healthcare workers and priority groups in poor countries.
Expressing his satisfaction with the WHO approval for the emergency use of the new Sinovac vaccine developed by China, Ghebreyesus said: “Today, I am happy to announce that the Sinovac-CoronaVac vaccine has been placed on the WHO emergency use list after being determined to be safe and effective. ” mentionned.
Ghebreyesus pointed out that “the quality of the Sinovac vaccine is finalized” after two doses.
PREVENTS HOSPITAL ADMISSIONS BY 100 PERCENT
In the statement, in which the results of the efficacy of the Sinovac vaccine were also shared, it was noted that 51% of those vaccinated prevented symptomatic illnesses.
In the statement, it was pointed out that severe cases and hospitalizations were prevented in 100 percent of people who studied the Sinovac vaccine.
The organization first announced on December 31 that the Kovid-19 vaccine produced by the Pfizer-BioNTech company, followed by the Oxford-AstraZeneca vaccine, the vaccine produced by the vaccine maker AstraZeneca Indian Serum Institute (SII), Astra ZenecaBio (South Korea), Moderna and Janssen, which authorized the emergency use of the vaccines it was producing.
Download the NTV application, be informed of developments